Key terms
About ALIM
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALIM news
Apr 19
9:20am ET
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)
Mar 25
7:44am ET
Alimera Sciences initiated with a Buy at Maxim
Mar 20
8:09am ET
Alimera Sciences reports inducement grants under Nasdaq listing rule
Mar 19
8:12am ET
Alimera announces first patient randomized in radiation retinopathy trial
Mar 08
12:25pm ET
Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials
Mar 08
12:17pm ET
Alimera Sciences price target raised to $6 from $5 at H.C. Wainwright
Mar 07
8:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)
Mar 07
7:32am ET
Alimera Sciences reports Q4 EPS (7c) vs (54c) last year
Feb 10
4:53am ET
Alimera Sciences Launches 2024 Equity Inducement Plan
Feb 09
6:16am ET
Buy Rating for Alimera’s Stock Amid Favorable NICE Guidance and Promising Clinical Trials
Feb 08
8:05am ET
Alimera announces NICE issued Final Draft Guidance on ILUVIEN
ALIM Financials
Key terms
Ad Feedback
ALIM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALIM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range